Introduction: Hematological malignancies (HM) are relatively frequent nosological entities within the structure of morbidity by malignant tumors, exhibiting a severe evolution, restrained prognosis and negative socio-economic impact in the advanced stages and phases. Objective: The objective of the study was to identify the epidemiological patterns, and to evaluate the epidemiological trends and disease burden issues of HM in the Republic of Moldova and worldwide. Materials and Methods: The following research methods were used: epidemiological, descriptive statistics, clinico-analytic. The diagnosis was proved in all cases by histopathological, cytological, cytogenetic, molecular and immunophenotyping examinations. The qualitative type researches were performed and enriched by the narrative synthesis of the data. From the specialized international bibliographic sources and official statistics concerning HM. The narrative review of the reference sources was fulfilled in the form of a synthesis. Results: The number of newly diagnosed and followed-up patients with HM at the Institute of Oncology in 2016, 2017, 2018, 2019, 2020 and 2021 amounted respectively to 725, 802, 613, 628, 536 and 528, the incidence (new cases per 100,000 population) being 17.6, 19.5, 14.9, 17.7, 15.1 and 20.3. In 2021 HM constituted 6.2% of all newly-diagnosed cases with malignant tumors in the Republic of Moldova. In the same year Hodgkin lymphoma was diagnosed in 10.04% of cases, non-Hodgkin’s lymphomas—in 31.63%, multiple myeloma and plasma cells neoplasms—in 7.77%, lymphoid leukemias—in 17.42%, myeloid leukemias—in 12.31%, monocytic leukemias—in 0.95%, and other leukemias—in 16.29%. In 2019 the male rate was 51.5%, and the female rate—48.5%. Within 2 years males were 266 (50.4%), females—262 (49.6%). The age of 50 - 79 years prevailed in both genders (males—65%, females—72.5%). The children constituted 4.0% of the newly diagnosed cases, 4.8% of those under the follow-up at the end of the year 2019 and 6.4% of the newly diagnosed cases in 2021. The disease span from the onset to diagnosis ranged between 1 - 24 months and constituted on average 5.63 months, without a significant difference as compared to 2019 (5.76 months). The incidence of HM in Western countries is 14 - 19 new cases per 100,000 population (4% of all cases with malignant tumors). The incidence of non-Hodgkin’s lymphomas increased by 45% between 2006 and 2016, from 319,078 to 461,000 cases. Between 2006 and 2016, the incidence of leukemias
References
[1]
Armitage, J.O., Gascoyne, R.D., Lunning, M.A., et al. (2017) Non-Hodgkin Lymphoma. The Lancet, 390, 298-310. https://doi.org/10.1016/S0140-6736(16)32407-2
[2]
Carbone, A. (2020) Classification of Tumors of the Hematopoietic and Lymphoid Tissues. Discovering Diseases—Defining Their Features. Bloods, 1, 7-9. https://doi.org/10.3390/bloods1010004
[3]
Fitzmaurice, C., et al. (2018) Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncology, 4, 1553-1568. https://doi.org/10.1001/jamaoncol.2018.2706
[4]
Mehta, J., et al. (2014) Epidemiology of Myeloproliferative Neoplasm in the United States. Leukemia & Lymphoma, 55, 595-600. https://doi.org/10.3109/10428194.2013.813500
[5]
Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics. CA: A Cancer Journal for Clinicians, 66, 7-30. https://doi.org/10.3322/caac.21332
[6]
Zelenetz, A.D., Gordon, L.I., Wierda, W.G., et al. (2014) National Comprehensive Cancer Network, Non-Hodgkin Lymphomas, Version 4.2014. Journal of the National Comprehensive Cancer Network, 12, 1282-1303. https://doi.org/10.6004/jnccn.2014.0125
[7]
Hughes, T.P., Ross, D.M. and Melo, J.V. (2016) Handbook of Chronic Myeloid Leukemia. Springer International Publishing, Berlin, 1-66.
[8]
Thompson, P.A., Kantarjian, H.M. and Cortes, J.E. (2015) Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. Mayo Clinic Proceedings, 90, 1440-1454. https://doi.org/10.1016/j.mayocp.2015.08.010
[9]
Moulard, O., et al. (2014) Epidemiology of Myelofibrosis, Essential Thrombocythemia, and Polycythemia Vera în the European Union. European Journal of Haematolology, 92, 289-297. https://doi.org/10.1111/ejh.12256
[10]
National Cancer Institute (2011) SEER Stat Fact Sheets: Leukemia. Surveillance, Epidemiology, and End Results (SEER) Program. http://seer.cancer.gov/statfacts/html/leuks.html
[11]
Saha, I. and Paul, B. (2020) Essentials of Biostatistics & Research Methodology. 3rd Edition, Academic Publishers, Kolkata, 1-398.
[12]
Swerdlow, S.H., Campo, E., Harris, N.L., et al. (2017) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition, IARC, Lyon.
[13]
Estey, E.H., Faderl, S.H. and Kantarjian, H.M. (2008) Hematologic Malignancies: Acute Leukemias. Springer, Berlin, 293 p. https://doi.org/10.1007/978-3-540-72304-2
[14]
Silver, R.T., Chow, W., Orazi, A., et al. (2013) Evaluation of WHO Criteria for Diagnosis of Polycythemia Vera: Prospective Analysis. Blood, 122, 1881-1886. https://doi.org/10.1182/blood-2013-06-508416
[15]
Rajkumar, V.S. (2018) Multiple Myeloma: 2018 Update on Diagnosis, Risk-Stratification, and Management. American Journal of Hematology, 93, 1091-1110. https://doi.org/10.1002/ajh.25117
[16]
Miranda-Filho, A., Piñeros, M., Znaor, A., Marcos-Gragera, R., et al. (2019) Globalpatterns and Trends in the Incidence of Non-Hodgkin Lymphoma. Cancer Causes & Control, 30, 489-499. https://doi.org/10.1007/s10552-019-01155-5
[17]
Tadmor, T., Liphshitz, I., Silverman, B. and Polliack, A. (2017) Incidence and Epidemiology of Non-Hodgkin Lymphoma and Risk of Second Malignancy among 22466 Survivors in Israel with 30 Years of Follow-Up. Hematological Oncology, 35, 599-607. https://doi.org/10.1002/hon.2302
[18]
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries: Global Cancer Statistics 2018. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
[19]
Perry, A.M., Diebold, J., Nathwani, B.N., et al. (2016) Non-Hodgkin Lymphoma in the Developing World: Review of 4539 Cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica, 101, 1244-1250. https://doi.org/10.3324/haematol.2016.148809
[20]
Yoon, S.O., Suh, C., Lee, D.H., Chi, H.S., Park, C.J., et al. (2010) Distribution of Lymphoid Neoplasms in the Republic of Korea: Analysis of 5318 Cases According to the World Health Organization Classification. American Journal of Hematology, 85, 760-764. https://doi.org/10.1002/ajh.21824
[21]
Chuang, S.S., Chen, S.W., Chang, S.T. and Kuo, Y.T. (2017) Lymphoma in Taiwan: Review of 1347 Neoplasms from a Single Institution According to the 2016 Revision of the World Health Organization Classification. Journal of the Formosan Medical Association, 116, 620-625. https://doi.org/10.1016/j.jfma.2016.11.006
[22]
Bassig, B.A., Cerhan, J.R., Au, W.Y., Kim, H.N., et al. (2015) Genetic Susceptibility to Diffuse Large B-Cell Lymphoma in a Pooled Study of three Eastern Asian Populations. European Journal of Haematology, 95, 442-448. https://doi.org/10.1111/ejh.12513
[23]
Cerhan, J.R. and Slager, S.L. (2015) Familial Predisposition and Genetic Risk Factors for Lymphoma. Blood, 126, 2265-2273. https://doi.org/10.1182/blood-2015-04-537498
[24]
Biagi, J.J. and Seymour, J.F. (2002) Insights into the Molecular Pathogenesis of Follicular Lymphoma Arising from Analysis of Geographic Variation. Blood, 99, 4265-4275. https://doi.org/10.1182/blood.V99.12.4265
[25]
Kim, J.S., Liu, Y., Hwa Ha, K., Qiu, H., et al. (2020) Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database. Cancer Research and Treatment, 52, 1262-1272. https://doi.org/10.4143/crt.2020.089
[26]
Farmanfarma, K.K., Kiasara, H.S., Hassanipour, S. and Salehiniya, H. (2020) Non-Hodgkin’s Lymphoma in the World: An Epidemiological Review. World Cancer Research Journal, 7, 1-6.
[27]
Leukemia & Lymphoma Society. Facts and Statistics Overview. https://www.lls.org/facts-and-statistics/facts-and-statistics-overview
[28]
Ye, X., Mahmud, S., Skrabek, P., Lix, L. and Johnston, J.B. (2017) Long-Term Time Trends in Incidence, Survival and Mortality of Lymphomas by Subtype among Adults in Manitoba, Canada: A Population-Based Study Using Cancer Registry Data. BMJ Open, 7, e015106. https://doi.org/10.1136/bmjopen-2016-015106
[29]
Luo, D., Zhou, T., Tao, Y., Feng, Y., Shen, X. and Mei, S. (2016) Exposure to Organochlorine Pesticides and Non-Hodgkin Lymphoma: A Meta-Analysis of Observational Studies. Scientific Reports, 6, Article No. 25768. https://doi.org/10.1038/srep25768
[30]
Howlader, N., Morton, L.M., Feuer, E.J., Besson, C. and Engels, E.A. (2016) Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends. Cancer Epidemiology, Biomarkers & Prevention, 25, 174-179. https://doi.org/10.1158/1055-9965.EPI-15-0921
[31]
Li, Y., Wang, Y., Wang, Z., Yi, D. and Ma, S. (2015) Racial Differences in Three Major NHL Subtypes: Descriptive Epidemiology. Cancer Epidemiology, 39, 8-13. https://doi.org/10.1016/j.canep.2014.12.001
[32]
Lin, L., Yan, L., Liu, Y., et al. (2019) Incidence and Death in 29 Cancer Groups in 2017 and Trend Analysis from 1990 to 2017 from the Global Burden of Disease Study. Journal of Hematology & Oncology, 12, 1-21. https://doi.org/10.1186/s13045-019-0783-9
[33]
Ning, L., Hu, C.h., Lu, P., et al. (2020) Trends in Disease Burden of Chronic Myeloid Leukemia at the Global, Regional, and National Levels: A Population-Based Epidemiologic Study. Experimental Hematology & Oncology, 9, 1-14. https://doi.org/10.1186/s40164-020-00185-z
[34]
Bower, H., Björkholm, M., Dickman, P.W., et al. (2016) Life Expectancy of Patients with Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. Journal of Clinical Oncology, 34, 2851-2857. https://doi.org/10.1200/JCO.2015.66.2866
[35]
Kutikova, L., Bowman, L., Chang, S., Long, S.R., et al. (2006) Medical Costs Associated with Non-Hodgkin’s Lymphoma in the United States during the First Two Years of Treatment. Leukemia & Lymphoma, 47, 1535-1544. https://doi.org/10.1080/10428190600573325
[36]
Yu, J.Y., Hansen, R.N., Valderrama, A. and Carlson, J.J. (2016) Indirect Costs and Workplace Productivity Loss Associated with Non-Hodgkin Lymphoma. Leukemia & Lymphoma, 57, 2636-2643. https://doi.org/10.3109/10428194.2016.1161187
[37]
Parasuraman, S.V., Naim, A.B., Paranagama, D.C., et al. (2015) Financial Burden of Myeloproliferative Neoplasms on Patients: Results from the MPN Landmark Survey in the United States. Blood, 126, 5561. https://doi.org/10.1182/blood.V126.23.5561.5561
[38]
Gallagher, C.J., Gregory, W.M., Jones, A.E., et al. (1986) Follicular Lymphoma: Prognostic Factors for Response and Survival. Journal of Clinical Oncology, 4, 1470-1480. https://doi.org/10.1200/JCO.1986.4.10.1470
[39]
Yu, J., Parasuraman, S.V., Paranagama, D.C., et al. (2018) Impact of Myeloproliferative Neoplasms on Patients’ Employment Status and Work Productivity in the United States: Results from the Living with MPNs Survey. BMC Cancer, 18, Article No. 420. https://doi.org/10.1186/s12885-018-4322-9
[40]
Harrison, C.N., Koschmieder, S., Foltz, L., et al. (2017) The Impact of Myeloproliferative Neoplasms (MPNs) on Patient Quality of Life and Productivity: Results from the International MPN Landmark Survey. Annals of Hematology, 96, 1653-1665. https://doi.org/10.1007/s00277-017-3082-y
[41]
Petrucci, M.T., Calabrese, E., Levi, A., et al. (2013) Cost of Illness in Patients with Multiple Myeloma in Italy: The CoMiM Study. Tumori, 99, e193-e202. https://doi.org/10.1177/030089161309900434
